Pharmaceuticals, intellectual property and free-trade: The case of the US-Australia free trade agreement

Prometheus: Critical Studies in Innovation

Volumn 22, Issue 3, 2004, Pages 243-257

  Drahos, Peter ^a   Lokuge, Buddhima ^b   Faunce, Thomas Alured ^b   Goddard, Martyn ^c   Henry, David ^d,e  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b The Australian National University   (Australia)

^c Australian National Council on AIDS   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e NEWCASTLE MATER HOSPITAL   (Australia)

Author keywords

Bargaining; Free trade agreements; Intellectual property; Pharmaceutical benefits scheme

Indexed keywords

FREE TRADE; INTELLECTUAL PROPERTY RIGHTS; MULTINATIONAL ENTERPRISE; PHARMACEUTICAL INDUSTRY; TRADE AGREEMENT;

AUSTRALASIA; AUSTRALIA; NORTH AMERICA; UNITED STATES;

EID: 4644226808     PISSN: 08109028     EISSN: None     Source Type: Journal    
DOI: 10.1080/0810902042000255705     Document Type: Article

References (33)

1. World Development Indicators Database, World Bank, April 2004.
2. Richard Adams, Philippa Dee, Jyothi Gali and Greg McGuire, The Trade and Investment Effects of Preferential Trading Arrangements, Productivity Commission, Staff Working Paper, Canberra, 2003.
3. Centre for International Economics, Economic Analysis of AUSFTA: Impact of the Bilateral Free Trade Agreement with the United States, April 2004.
4. 'Free trade deal will cost thousands of jobs', The Age, 7 June 2004.
5. P. Drahos and J. Braithwaite, Information Feudalism: Who Owns the Knowledge Economy?, Earthscan Publications, London, 2002.
6. The National Medicines Policy 2000, Department of Health and Ageing, Commonwealth of Australia, 1999, p. 1.
7. Robert Cooter and Thomas Ulen, Law and Economics, 3rd edition, Addison Wesley Longman, Reading, MA, 2000, pp. 262-3.
8. Productivity Commission, International Pharmaceutical Price Differences, available through http://www.pc.gov.au;
9. 'Prescriptions may rise 30% under FTA: academic', The Sydney Morning Herald, 20 May 2004.
10. G. Tambling et al., Final Report of the Review of PBS Listing Arrangements by Senator Tambling Review Group, Department of Health and Aged Care, Canberra, 2000 (unpublished).
11. K. Schneeman, Medicines Australia Welcomes FTA Announcement, media release, Medicines Australia, Canberra, 9 February 2004.
12. G. Gamble et al., The US-Australia Free Trade Agreement: Report of the Industry Sector Advisory Committee for Chemicals and Allied Products (ISAC-3), 12 March 2004.
13. J. Braithwaite and P. Drahos, Global Business Regulation, Cambridge University Press, Cambridge, 2000, ch. 21.
14. Gregory Shaffer, Defending Interests: Public-Private Partnerships in WTO Litigation, Brookings Institution Press, Washington, DC, 2003.
15. S. Sell, Private Power, Public Law: the Globalization of Intellectual Property Rights, Cambridge University Press, Cambridge, 2003, ch. 4.
16. http://www.ustr.gov.
17. R. Balance, J. Pogány and H. Forstner, The World's Pharmaceutical Industries, Edward Elgar, Aldershot, Hants, England and Brookfield, VT, USA, 1992.
18. Carlos Correa, 'Public health and patent legislation in developing countries', Tulane Journal of Technology and Intellectual Property, 3, 2001, pp. 43-9.
19. F. M. Scherer, The Economic Effects of Compulsory Licensing, The Monograph Series in Finance and Economics, New York University, 1977.
20. J. Lexchin, 'After compulsory licensing: coming issues in Canadian pharmaceutical policy and politics', Health Policy, 40, 1997, pp. 69-80.
21. C. Correa, Protection of Data Submitted for the Registration of Pharmaceuticals: Implementing the Standards of the TRIPS Agreement, South Centre, 2002, p. xi.
22. Carlos Correa, Integrating Public Health Concerns into Patent Legislation in Developing Countries, South Centre, 2000, p. 53.
23. Generic Drug Entry Prior to Patent Expiration, Federal Trade Commission, July 2002.
24. Collusion and Other Anticompetitive Practices: A Survey of Class Action Lawsuits Against Drug Manufacturers, 3rd edition, January 2004, Families USA, p. 18.
25. P. Drahos and I. Maher (eds), 'Innovation, Competition, Standards and Intellectual Property: Policy Perspectives from Economics and Law', Special Issue of Information Economics and Policy, 16, 2004, pp. 1-158.
26. B. Lokuge, T. Faunce and R. Denniss, A Backdoor to Higher Medicine Prices? Intellectual Property and the Australia-US Free Trade Agreement, Australia Institute, Canberra, November 2003.
27. Productivity Commission, International Pharmaceutical Price Differences, Research Report, Canberra, 2001, p. 79.
28. B. Lokuge, R. Denniss et al., Comparing Drug Prices in Australia and the USA, The Australia Institute, Canberra, 2003.
29. PBS Prescription and Expenditure Statistics Year Ending December 2003, Department of Health and Ageing, Canberra, 2003.
30. 'Remarks of Mr Emory Simon, Symposium: Trade-Related Aspects of Intellectual Property', Vanderbill Journal of Transnational Law, 22, 1989, p. 370.
31. P. Drahos, 'BITs and BIPs-bilateralism in intellectual property', Journal of World Intellectual Property, 4, 2001, pp. 791-808.
32. Peter A. Hall and David Soskice (eds), Varieties of Capitalism: The Institutional Foundations of Comparative Advantage, Oxford University Press, Oxford, 2001.
33. P. Drahos and J. Braithwaite, 'Intellectual property, corporate strategy, globalisation: TRIPS in context', Wisconsin International Law Journal, 20, 2002, pp. 451-80.